Cancer
EGFR tyrosine kinase inhibitors
Targeted drugs that block the epidermal growth factor receptor kinase; highly effective in lung adenocarcinomas carrying activating EGFR mutations, which is why tumours are tested before treatment.
Mécanisme d’action
- EGFR is a receptor tyrosine kinase; activating mutations (exon 19 deletions, L858R) switch it on permanently, driving growth through RAS–MAPK and PI3K–AKT.
- Gefitinib and erlotinib compete with ATP at the kinase site; osimertinib binds irreversibly and also blocks the T790M resistance mutation.
- Tumours "addicted" to the mutant receptor shrink rapidly.
Cibles moléculaires
- EGFR tyrosine kinase: Inhibitor
Médicaments : EGFR tyrosine kinase inhibitors
First generation (reversible)
- Gefitinib (First generation.)
- Erlotinib (First generation.)
Second generation (irreversible)
- Afatinib (Second generation, irreversible.)
Third generation
- Osimertinib (Third generation; preferred first-line.)
Indications thérapeutiques
- Non-small cell lung cancer (usually adenocarcinoma) with an activating EGFR mutation
- After surgery for resected EGFR-mutant lung cancer (osimertinib)
Maladies traitées
Effets indésirables
- Acneiform rash
- Diarrhoea
- Interstitial lung disease (rare)
- QT prolongation (osimertinib)
Contre-indications selon le terrain
- Interstitial lung disease (Avec précaution): Pneumonitis is more likely.
- Liver cirrhosis (Avec précaution): They are cleared by the liver.
- Pregnancy (Contre-indiqué): They harm the fetus.
Autres précautions et interactions
- They do not help tumours without the mutation: molecular testing comes first.
- Acid-suppressing drugs reduce the absorption of gefitinib and erlotinib; smoking lowers erlotinib levels.
Rédigé d’après
- Lippincott Illustrated Reviews: Pharmacology, 7th ed., Ch. 35, Anticancer Drugs, Tyrosine kinase inhibitors
- Basic & Clinical Pharmacology (Katzung), 14th ed., Ch. 54, Cancer Chemotherapy, Tyrosine kinase inhibitors
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.